drugset
drugset / Trial / NCT01358006

A Dose-Ranging Study of JNJ-40411813 in Healthy Male Volunteers

NCT01358006 ↗

Phase 1 Completed 13 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
NaSingle-groupOpen-label

Summary

The purpose of this study is to characterize the 5-HT2A binding over the maximum feasible dose range of JNJ-40411813, to estimate the plasma concentration associated with 50% 5-HT2A binding, and to investigate the safety and tolerability of JNJ-40411813 in healthy male volunteers.

Timeline

Start
2010-11
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-40411813 Small molecule 200 mg Oral
Subject JNJ-40411813 Small molecule 300 mg Oral
Subject JNJ-40411813 Small molecule 700 mg Oral

Indications

No indication recorded.